Using a special emulsion to protect the brain during a stroke
Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke
This study is looking at a new treatment called NanO2™ that might help protect the brain during an ischemic stroke, and it's for patients who are receiving standard care like thrombectomy and tPA, to see if it can improve their recovery and brain function.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nuvox Pharma, LLC NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11060992 on NIH RePORTER |
What this research studies
This research investigates the use of a novel emulsion called NanO2™ (dodecafluoropentane emulsion) as a potential cerebroprotectant for patients experiencing ischemic strokes. The approach involves administering this emulsion intravenously within a critical time frame after stroke onset to preserve brain function and reduce damage. The study aims to evaluate the safety and effectiveness of NanO2™ in combination with standard treatments like mechanical thrombectomy and tPA. Patients will be monitored for improvements in neurological function and overall recovery.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults experiencing an ischemic stroke, particularly those who can receive treatment within a few hours of symptom onset.
Not a fit: Patients who have had a stroke for more than five hours or those with hemorrhagic strokes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces brain damage and improves recovery outcomes for stroke patients.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating that this method could be a viable option for stroke treatment.
Where this research is happening
Tucson, United States
- Nuvox Pharma, LLC — Tucson, United States (Active)
Researchers
- Principal investigator: Unger, Evan Charles — Nuvox Pharma, LLC
- Study coordinator: Unger, Evan Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.